Our top pick for
Building a portfolio
Medicenna Therapeutics Corp is a biotechnology business based in the US. Medicenna Therapeutics shares (MDNA) are listed on the NASDAQ and all prices are listed in US Dollars. Medicenna Therapeutics employs 7 staff and has a market cap (total outstanding shares value) of 0.00.
|52-week range||$2.20 - $6.84|
|50-day moving average||$3.97|
|200-day moving average||$4.05|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||$0|
|Return on assets TTM||-41.1%|
|Return on equity TTM||-71.85%|
|Market capitalisation||$216.1 million|
TTM: trailing 12 months
There are currently 268,568 Medicenna Therapeutics shares held short by investors – that's known as Medicenna Therapeutics's "short interest". This figure is 45.2% up from 184,976 last month.
There are a few different ways that this level of interest in shorting Medicenna Therapeutics shares can be evaluated.
Medicenna Therapeutics's "short interest ratio" (SIR) is the quantity of Medicenna Therapeutics shares currently shorted divided by the average quantity of Medicenna Therapeutics shares traded daily (recently around 172158.97435897). Medicenna Therapeutics's SIR currently stands at 1.56. In other words for every 100,000 Medicenna Therapeutics shares traded daily on the market, roughly 1560 shares are currently held short.
However Medicenna Therapeutics's short interest can also be evaluated against the total number of Medicenna Therapeutics shares, or, against the total number of tradable Medicenna Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Medicenna Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Medicenna Therapeutics shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Medicenna Therapeutics shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Medicenna Therapeutics.
Find out more about how you can short Medicenna Therapeutics stock.
We're not expecting Medicenna Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Medicenna Therapeutics's shares have ranged in value from as little as $2.195 up to $6.84. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Medicenna Therapeutics's is 0.6631. This would suggest that Medicenna Therapeutics's shares are less volatile than average (for this exchange).
Medicenna Therapeutics Corp. , a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that is in the Phase 2b clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA57 for solid tumors and non-malignant cells of the tumor micro-environment; MDNA109, an IL-2 agonist to treat cancer immunotherapies; MDNA209, an IL-2 antagonist for autoimmune diseases; MDNA413, a dual IL-4/IL-13 antagonist for the treatment of solid tumors, atopic dermatitis, asthma, and fibrosis; and MDNA132, an IL-13 agonist to treat solid tumors and IL 13Ralpha2 chimeric antigen receptor T cell. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada. .
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZIONL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.